Number of the records: 1
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor Vildagliptin in patients with Type 2 Diabetes
Title Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor Vildagliptin in patients with Type 2 Diabetes Author AZUMA K. Co-authors Rádiková Žofia SAVEXEND - Ústav experimentálnej endokrinológie SAV SCOPUS RID ORCID He Y. Co-authors MANCINO J. TOLEDO FG THOMAS E KANGANI C. DALLA MAN C. COBELLI C. HOLST JJ. DEACON CF LIGUEROS-SAYLAN M SERRA D. FOLEY JE KELLEY DE Source document Journal of Clinical Endocrinology & Metabolism. Vol. 93, no. 2 (2008), p. 459-464 Language eng - English Country US - United States of America Document kind rozpis článkov z periodík (rbx) Citations Ahren B: Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. EXPERT OPINION ON EMERGING DRUGS 13 (4): 593-607, 2008. RHEE, E.J., LEE, W.Y., YOON, K.H., YOO, S.J., LEE, I.K., BAIK, S.H., KIM, Y.K., LEE, M.K., PARK, K.S., PARK, J.Y., CHA, B.S., LEE, H.W., MIN, K.W., BAE, H.Y., KIM, M.J., KIM, J.A., KIM, D.K., KIM, S.-W. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 12(12): 1113-1119, 2010 AYALA, J.E., BRACY, D.P., JAMES, F.D., BURMEISTER, M.A., WASSERMAN, D.H., DRUCKER, D.J. Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 151(10): 4678-4687, 2010 HE, Y.-L., YAMAGUCHI, M., ITO, H., TERAO, S., SEKIGUCHI, K. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. International Journal of Clinical Pharmacology and Therapeutics 48(9): 582-595, 2010 GRAU, K., CAUCHI, S., HOLST, C., ASTRUP, A., MARTINEZ, J.A., SARIS, W.H.M., BLAAK, E.E., OPPERT, J.-M., ARNER, P., RÖSSNER, S., MACDONALD, I.A., KLIMCAKOVA, E., LANGIN, D., PEDERSEN, O., FROGUEL, P., SORENSEN, T.I.A. TCF7L2 rs7903146-macronutrient interaction in obese individuals' responses to a 10-wk randomized hypoenergetic diet. American Journal of Clinical Nutrition 91(2): 472-479, 2010 2. Croxtall JD, Keam SJ Vildagliptin: A review of its use in the management of type 2 diabetes mellitus. DRUGS 68(16): 2387-2409, 2008. TAHRANI, A.A., PIYA, M.K., KENNEDY, A., BARNETT, A.H. Glycaemic control in type 2 diabetes: Targets and new therapies. Pharmacology and Therapeutics 125(2): 328-361, 2010 KEATING, G.M. VILDAGLIPTIN: A review of its use in type 2 diabetes mellitus. Drugs 70(16): 2089-2112, 2010 MIURA, K., KITAHARA, Y., YAMAGISHI, S. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in zucker fatty rats. Hormone and Metabolic Research 42(10): 731-735, 2010 COX, M.E., ROWELL, J., CORSINO, L., GREEN, J.B. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: Safety, tolerability, and efficacy. Drug, Healthcare and Patient Safety 2(1): 7-19, 2010 3. Krentz AJ, Patel MB, Bailey CJ: New drugs for type 2 diabetes mellitus: What is their place in therapy? DRUGS, 68 (15): 2131-2162, 2008. 5. Schmitz, O: The GLP-1 concept in the treatment of type 2 diabetes - Still standing at the gate of dawn? JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 93(2): 375-377, 2008. Mikhail N: Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes. THEORETICAL CONSIDERATION AND THERAPEUTIC POTENTIAL.VASCULAR HEALTH AND RISK MANAGEMENT 4(6): 1221- 1227, 2008. Mathieu C, Degrande E, Vildagliptin: A new oral treatment for type 2 diabetes mellitus. VASCULAR HEALTH AND RISK MANAGEMENT 4(6): 1349-1360, 2008. ZHONG, Jixin - MAISEYEU, Andrei - RAJAGOPALAN, Sanjay. Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors. In CLINICAL LIPIDOLOGY. ISSN 1758-4299, 2015, vol. 10, no. 1, pp. 103-112. ZHENG, T. P. - LIU, Y. H. - YANG, L. X. - QIN, S. H. - LIU, H. B. Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of subclinical atherosclerosis in Chinese patients with newly diagnosed type 2 diabetes: A cross-sectional study. In ATHEROSCLEROSIS. ISSN 0021-9150, 2015, vol. 242, no. 2, pp. 580-588. CAI, Xiaoling - HAN, Xueyao - LUO, Yingying - JI, Linong. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on beta-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis. In JOURNAL OF DIABETES. ISSN 1753-0393, 2015, vol. 7, no. 3, pp. 347-359. BAEK, Jong-Ha - JIN, Sang-Man - KAKU, Kohei - JUNG, Jin-Ah - KIM, Jung-Ryul - KO, Jae-Wook - KIM, Min-Ji - LEE, Soo-Youn - HUH, Woo-seong - KIM, Jae Hyeon. Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment. In EXPERT OPINION ON PHARMACOTHERAPY. ISSN 1465-6566, 2015, vol. 16, no. 8, pp. 1127-1136. YUAN, Guoyue - HU, Hao - WANG, Su - YANG, Qichao - YU, Shuqin - SUN, Wenjun - QIAN, Weiyun - MAO, Caoming - ZHOU, Libin - CHEN, Dezhi - WANG, Zhaoling - GONG, Qin - WANG, Dong. Improvement of beta-cell function ameliorated glycemic variability in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion or in combination with sitagliptin treatment: a randomized control trial. In ENDOCRINE JOURNAL. ISSN 0918-8959, 2015, vol. 62, no. 9, pp. 817-834. LIM, Sun W. - JIN, Long - PIAO, Shang G. - CHUNG, Byung H. - YANG, Chul W. Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury. In LABORATORY INVESTIGATION. ISSN 0023-6837, 2015, vol. 95, no. 10, pp. 1174-1185. EL BEKAY, Rajaa - COIN-ARAGUEZ, Leticia - FERNANDEZ-GARCIA, Diego - OLIVA-OLIVERA, Wilfredo - BERNAL-LOPEZ, Rosa - CLEMENTE-POSTIGO, Mercedes - DELGADO-LISTA, Javier - DIAZ-RUIZ, Alberto - GUZMAN-RUIZ, Rocio - VAZQUEZ-MARTINEZ, Rafael - LHAMYANI, Said - MAR ROCA-RODRIGUEZ, Maria - FERNANDEZ VELEDO, Sonia - VENDRELL, Joan - MALAGON, Maria M. - JOSE TINAHONES, Francisco. Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes. In BRITISH JOURNAL OF PHARMACOLOGY. ISSN 0007-1188, 2016, vol. 173, no. 11, pp. 1820-1834. PARTHAN, Girish - BHANSALI, Shobhit - KURPAD, Anura - WALIA, Rama - BHAT, Kishor - BHANSALI, Anil. Effect of Lingliptin and Voglibose on metabolic Profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial. In BMC PHARMACOLOGY & TOXICOLOGY. ISSN 2050-6511, 2018, vol. 19, no., pp. MIN, Se Hee - YOON, Jeong-Hwa - HAHN, Seokyung - CHO, Young Min. Efficacy and safety of combination therapy with an alpha-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis. In JOURNAL OF DIABETES INVESTIGATION. ISSN 2040-1116, 2018, vol. 9, no. 4, pp. 893-902. SHANKAR, Sudha S. - SHANKAR, R. Ravi - MIXSON, Lori A. - MILLER, Deborah L. - STEINBERG, Helmut O. - BEALS, Chan R. - KELLEY, David E. Insulin secretory effect of sitagliptin: assessment with a hyperglycemic clamp combined with a meal challenge. In AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM. ISSN 0193-1849, 2018, vol. 314, no. 4, pp. E406-E412. HAEDERSDAL, Sofie - LUND, Asger - KNOP, Filip K. - VILSBOLL, Tina. The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. In MAYO CLINIC PROCEEDINGS. ISSN 0025-6196, 2018, vol. 93, no. 2, pp. 217-239. EJARQUE, Miriam - GUERRERO-PEREZ, Fernando - DE LA MORENA, Nuria - CASAJOANA, Anna - VIRGILI, Nuria - LOPEZ-URDIALES, Rafael - MAYMO-MASIP, Elsa - PUJOL GEBELLI, Jordi - RUIZ DE GORDEJUELA, Amador Garcia - PEREZ-MARAVER, Manuel - PELLITERO, Silvia - FERNANDEZ-VELEDO, Sonia - VENDRELL, Joan - VILARRASA, Nuria. Role of adipose tissue GLP-1R expression in metabolic improvement after bariatric surgery in patients with type 2 diabetes. In SCIENTIFIC REPORTS. ISSN 2045-2322, 2019, vol. 9, no., pp. LIU, X. - LIU, Y. - LIU, H.Z. - LI, H.Y. - YANG, J.H. - HU, P. - XIAO, X.H. - LIU, D.Y. Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes. In FRONTIERS IN ENDOCRINOLOGY. ISSN 1664-2392, SEP 20 2021, vol. 12. WU, M. - LI, Q.Q. - ZHANG, H. - ZHU, X.X. - LI, X.J. - LI, Y. - SUN, H.G. - DING, Y.H. Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus. In CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT. ISSN 2160-7648, JUN 2021, vol. 10, no. 6, p. 660-668. SUBRAHMANYAN, N.A. - KOSHY, R.M. - JACOB, K. - PAPPACHAN, J.M. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors. In CURRENT DRUG SAFETY. ISSN 1574-8863, 2021, vol. 16, no. 2, p. 154-164. OKURA, T. - FUJIOKA, Y. - NAKAMURA, R. - ITO, Y. - KITAO, S. - ANNO, M. - MATSUMOTO, K. - SHOJI, K. - OKURA, H. - MATSUZAWA, K. - IZAWA, S. - UETA, E. - KATO, M. - IMAMURA, T. - TANIGUCHI, S.I. - YAMAMOTO, K. Dipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: a single-arm study, a brief report. In DIABETOLOGY & METABOLIC SYNDROME. JUN 7 2022, vol. 14, no. 1. Dostupné na: https://doi.org/10.1186/s13098-022-00850-9. LIN, W.R. - LIU, K.H. - LING, T.C. - WANG, M.C. - LIN, W.H. Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease. In WORLD JOURNAL OF DIABETES. APR 15 2023, vol. 14, no. 4, p. 352-363. Dostupné na: https://doi.org/10.4239/wjd.v14.i4.352. KURKIN, D.V. - BAKULIN, D.A. - MORKOVIN, E.I. - STRYGIN, A.V. - GORBUNOVA, Y.V. - VOLOTOVA, E.V. - MAKARENKO, I.I. - SAPAROVA, V.B. - DRAI, R.V. - PETROV, V.I. Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use. In PHARMACY & PHARMACOLOGY-FARMATSIYA I FARMAKOLOGIYA. ISSN 2307-9266, 2023, vol. 11, no. 1, p. 19-47. Dostupné na: https://doi.org/10.19163/2307-9266-2023-11-1-19-47. Category ADCA - Scientific papers in foreign journals registered in Current Contents Connect with IF (impacted) Category of document (from 2022) V3 - Vedecký výstup publikačnej činnosti z časopisu Type of document článok Year 2008 Registered in WOS Registered in SCOPUS Registered in CCC DOI 10.1210/jc.2007-1369 
article
rok CC IF IF Q (best) JCR Av Jour IF Perc SJR SJR Q (best) CiteScore A rok vydania rok metriky IF IF Q (best) SJR SJR Q (best) 2008 2007 5.493
Number of the records: 1